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Pharmacoeconomic and clinical
implications of sequential therapy for
metastatic renal cell carcinoma
patients in Central and Eastern Europe
E Vrdoljak †, L Torday, C Szczylik, G Kharkevich, S Bavbek & A Sella
†University Hospital Split, Department of Oncology, Split, Croatia
Introduction: The incidence and mortality rates of kidney cancer in the
Central and Eastern European (CEE) region are among the highest in the
world. Access to second and subsequent lines of metastatic renal cell carci-
noma (mRCC) therapies is highly varied in the region. Despite the increasing
body of evidence supporting the clinical benefit of multiple lines of treat-
ment, access to treatment beyond first line is restricted in many of these
countries.
Areas covered: The adoption of targeted therapies for the first-line treat-
ment of mRCC in the region was slow and faced many obstacles. In order to
evaluate the current status of treatment beyond the first-line setting in the
CEE region, this review examines the availability and reimbursement of mRCC
drugs and clinical practice in institutions that treat patients with mRCC.
Expert opinion: This review highlights the need to raise awareness among
physicians, payers and regulators on clinical trial and cost-effectiveness data
regarding the treatment of mRCC beyond the first line. The obstacles to
mRCC drug access highlighted in this review need to be overcome to ensure
that patients are receiving the best treatment available.
Keywords: axitinib, cytokines, everolimus, metastatic renal cell carcinoma, molecular-targeted
agents, pazopanib, receptor tyrosine kinase inhibitors, sorafenib, sunitinib, temsirolimus
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1. Introduction
Cancer incidence and mortality rates in the Central and Eastern European (CEE)
region are among the highest in Europe and are increasing. Immediate action –
such as the implementation of best practice strategies encompassing primary pre-
vention, early detection, and the use of the best available treatments – is required to
tackle these problems.[1–5] However, the limited availability of healthcare
resources in countries with transitioning economies is a main obstacle to the
effective management of patients with cancer.[6]
Economies in the CEE region are transitioning: gross domestic product per
capita in CEE countries ranges from 1.2- to 9.1-fold lower than the EU’s Big 5
(France, Germany, Italy, Spain and the UK).[7, 8] To further compound the high
rates of cancer mortality, healthcare expenditure per capita in CEE countries is
considerably lower – ranging from 607.6 USD in Kazakhstan to 2046 USD in the
Czech Republic – than in the EU’s Big 5, where it ranges from 3040.1 to 4617
USD.[9]
Renal cell carcinoma (RCC) accounts for ~90% of kidney malignancies and 2 –
3% of all adult malignancies.[10, 11] The global incidence of RCC continues to
gradually rise, with 209,000 new cases and 102,000 deaths reported per year.[10]
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Rates in the CEE region are among the highest in Europe
and the world according to estimates made by the
International Agency for Research on Cancer in 2012.[12]
Among the CEE countries considered in this review, the
Czech Republic reports the highest rates of kidney cancer
incidence and mortality, followed by Slovakia and Belarus.
[12] The reasons for the high RCC incidence in the region
are not fully understood but may be related in part to
external risk factors.[7]
At present, the main aim of treatment in advanced RCC/
metastatic RCC (mRCC) is to extend both progression-free
survival (PFS) and overall survival (OS) with the fewest
adverse events (AEs) while maintaining the best possible
quality of life (QoL).[13, 14] In the past decade, the intro-
duction of targeted agents has dramatically improved the PFS
and OS of patients with mRCC compared with that observed
during the cytokine era; such improvements suggest that it
may be possible to convert mRCC into a chronic disease in
some cases.[13,15,16] To obtain maximum benefit from
targeted agents in the treatment of mRCC, it is essential
that healthcare professionals have the knowledge to select
the appropriate choice of treatment/treatment sequence and
to effectively manage patients receiving targeted therapies.
[10,17]
Targeted agents are the standard of care in all lines of
therapy.[10,11] The significant benefits of first-line therapy
with targeted agents are well documented and increasing
attention is now focused on optimal therapeutic options
following disease progression.[15] Disease progression can
result from developing resistance to first-line therapy;[15]
however, the use of agents from the same class can be
effective in subsequent lines of therapy.[18] To gain max-
imum benefit from targeted therapies, the patient should be
closely monitored throughout treatment to ensure decisions
appropriate to the individual’s needs are made.[19] An
important component of this is the selection of second-line
therapy.
2. Overview of current treatment options second
line and beyond for mRCC
Current European Society for Medical Oncology (ESMO)
guidelines recommend the use of several lines of targeted
treatment for the management of patients with advanced
RCC/mRCC.[10] Two options are recommended as stan-
dard second-line therapy after VEGF-targeted therapy: the
VEGF-tyrosine kinase inhibitor (TKI), axitinib or the mam-
malian target of rapamycin (mTOR) inhibitor, everolimus.
[10] In addition, ESMO guidelines recommend everolimus
as third-line treatment in patients previously treated with two
TKIs or a TKI and bevacizumab plus IFN-α. Although first-
line IFN-α usage is limited, axitinib is also recommended for
use post cytokines.
Appropriate treatment sequencing can optimize out-
comes in patients with mRCC.[13,20–23] Clinical trials
investigating the use of sequential treatment strategies in
mRCC have shown that single targeted agents can cause
tumor shrinkage, slow disease progression and demonstrate
significant PFS and QoL benefits.[18,24,25] The benefit
of targeted therapy second line and beyond in patients
with mRCC has been demonstrated through the analysis
of data from 2705 patients, obtained from the
International mRCC Database Consortium, which indi-
cated that patients who are able to receive more lines of
targeted therapy live longer than those who receive fewer.
[26] Despite the overlapping targets of TKIs, numerous
studies have demonstrated the efficacy of sequential TKI
therapies.[18,27,28] Similarly, mTOR-inhibitor usage fol-
lowing TKI therapy extends PFS compared with placebo
in the second line.[24]
2.1 Post-VEGF inhibition:TKI and mTOR inhibitors
Axitinib, which is a more specific and potent VEGF-TKI
than sunitinib, sorafenib or pazopanib, is approved as a
second-line treatment in many countries.[29–31] The effi-
cacy and safety of axitinib as a second-line treatment for
patients with clear cell mRCC was compared with sorafenib
in the Phase III randomized trial, AXIS.[18,25] It is worth
noting that pazopanib was not available when this trial was
designed, so the trial does not provide evidence for the
efficacy of second-line axitinib after first-line pazopanib.
In the AXIS trial, most patients (389/723) received first-
line sunitinib as recommended in the ESMO guidelines,
Article highlights.
● The incidence and mortality rates of renal cell carcinoma
(RCC) in the Central and Eastern European (CEE) region
are among the highest in the world.
● The use of sequential targeted therapies has been shown
to be highly clinically beneficial for patients with meta-
static RCC (mRCC).
● There are many obstacles to the use of second-line and
beyond therapies in the CEE region, owing to the limited
availability of drugs, reimbursement restrictions, lack of
cost-effectiveness data for mRCC drugs and the com-
plexity of some reimbursement systems.
● Increasing awareness of clinical trial and cost-effective-
ness data as well as tackling obstacles regarding
reimbursement restrictions will increase the number of
treatment options available to patients with mRCC in the
CEE region.
● Increased access to optimal treatment strategies will be
highly effective in tackling the high mortality rates asso-
ciated with mRCC in this region.
● The situation regarding access to second-line therapies in
Russia is considered separately in Box 1.
This box summarizes key points contained in the article.
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reinforcing the relevance of the data to the effective man-
agement of patients with mRCC.[10,18,25] The primary
end point, PFS, was significantly improved in the axitinib
arm compared with the sorafenib arm [6.7 vs 4.7 months;
hazard ratio (HR) = 0.665; p < 0.001].[25] Although there
was no significant difference in OS between arms, this
may have been confounded by subsequent active treat-
ments after progression. The investigator-assessed objective
response rate reported with the use of axitinib in the AXIS
trial was 23%.[18] The data obtained also evidenced the
distinct safety profiles of axitinib and sorafenib.[18] The
most common Grade III or higher treatment-related AEs
associated with axitinib were hypertension, fatigue and
diarrhea compared with hand–foot syndrome, hyperten-
sion and diarrhea in the sorafenib arm. Importantly, the
proportion of patients who experienced Grade III or
higher hand–foot syndrome in the sorafenib treatment
arm was nearly three times that of those treated with
axitinib (17 vs 6%).
In a Phase III trial, (RECORD-1), the superiority of ever-
olimus over placebo in second line and beyond was demon-
strated in 416 patients. PFS was prolonged in the everolimus
arm compared with the placebo arm (4.9 vs 1.9 months;
HR = 0.33; p < 0.001).[24] It is also worth noting that
everolimus prolonged PFS compared with placebo (4.0 vs
1.8 months; HR = 0.32) in patients who had received two
prior lines of TKI treatment (sunitinib and sorafenib).[24] In
addition, most patients (79%) received everolimus in third
line or beyond; thus, the results of this trial provide evidence
that everolimus is effective following two or more lines of
VEGF-targeted treatment.[24] Again, pazopanib was not
available when this trial was designed so it does not provide
any evidence of the efficacy of second- and subsequent-line
everolimus after first-line pazopanib. This increases the num-
ber of treatment options for patients because everolimus
would be expected to be effective following treatment with
axitinib in the second line; it is recommended in this setting
in the ESMO guidelines.[10] The median OS did not sig-
nificantly differ between the two treatment arms; however, as
in many trials, this is probably because of patients from the
placebo group crossing over to receive everolimus.[24]
Infections, dyspnea, stomatitis and fatigue were the most
common Grade III or higher treatment-related AEs with
everolimus.
In a randomized Phase III trial (INTORSECT) invol-
ving 512 patients, there was no significant difference in
median PFS after first-line sunitinib: 4.3 months with
temsirolimus compared with 3.9 months with sorafenib
(p = 0.19).[27] Despite this, median OS was significantly
longer (p = 0.01) in patients treated in the second line
with the TKI sorafenib (16.6 months) than with the
mTOR inhibitor temsirolimus (12.3 months) following
disease progression with first-line sunitinib treatment
(HR = 1.31; 95% CI 1.05 – 1.63).[27]
2.2 Post-cytokine therapy
Cytokines are no longer considered the standard of care as
first-line mRCC therapy; however, the efficacy of TKI thera-
pies axitinib, sorafenib, pazopanib and sunitinib in patients
with cytokine-refractory mRCC has been demonstrated in
various studies.[32–36]
2.3 Treatment strategies beyond first line: ‘real-world’
retrospective analyses
In the absence of comparative trials, real-world experience
can provide valuable insights into treatment strategies. For
example, the Czech Clinical Registry of Renal Cell Cancer
Patients (RENIS) is a highly valuable resource, providing
information on the treatment of patients with mRCC that
is particularly relevant to the CEE region.[20–23, 32] Data
of 218 patients with mRCC treated with sunitinib and
sorafenib obtained from RENIS showed a strong correlation
between responses to first- versus second-line VEGF inhi-
bitor (p < 0.001); however, duration of response on the
first-line VEGF-targeted therapy was not a valuable indica-
tor of response to second-line VEGF-targeted therapy.[22]
Whereas retrospective analysis of data from the
International mRCC Database Consortium on 464 patients
with mRCC who had been treated with VEGF inhibitors in
the first and second line demonstrated that patients can
benefit from second-line VEGF-targeted therapy regardless
of the response in first line.[37] In this study, there was
neither an association between partial response, stable dis-
ease, or progressive disease rates in the first- and second-line
setting (p = 0.17) nor any correlation between median PFS
in the first and second line (p = 0.59). The RENIS registry
data were also used to compare the efficacy of the sequences
sorafenib followed by sunitinib (n = 122), or sunitinib
followed by sorafenib (n = 138). There was no significant
difference in PFS between patients treated with sorafenib–
sunitinib (18.8 months) compared with sunitinib–sorafenib
(17.7 months; p < 0.47).[20]
At present, there is limited and conflicting evidence
regarding the optimal second-line treatment. A large, multi-
center analysis involving 2106 patients from 12 cancer
centers compared the use of VEGF inhibitor–VEGF inhi-
bitor with VEGF inhibitor–mTOR inhibitor sequence;
however, these results were not definitive because there
was no significant difference in patient outcomes.[38]
Conversely, in a systematic review and meta-analysis, a
significantly longer OS was reported following second-line
treatment with mTOR inhibitor compared with VEGF-
TKI (HR = 0.82; p = 0.028).[39] It is important to note,
firstly, that >60% of patients were treated with sorafenib
and none with axitinib in the second-line VEGF-TKI
group; and secondly, significant heterogeneity (p = 0.001)
in estimated second-line treatment effects was reported.
A retrospective study analyzed data obtained from 23
centers in Italy involving 2065 patients treated with up to
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three consecutive lines of therapy in one of the following
sequences: VEGF inhibitor–VEGF inhibitor–mTOR inhibi-
tor or VEGF inhibitor–mTOR inhibitor–VEGF inhibitor
[40]; this study was also included in the aforementioned
systematic review.[39] VEGF inhibitors included sunitinib,
sorafenib, pazopanib, axitinib and bevacizumab plus IFN-α;
mTOR inhibitors included temsirolimus and everolimus. Of
the 2065 patients, 281 received three lines of targeted
therapy. Both median combined PFS and median OS
were longer, the latter being significantly longer
(p = 0.004), in patients treated with VEGF inhibitor–
VEGF inhibitor–mTOR inhibitor (mTOR inhibitor: OS
36.5 months; PFS 50.7 months) than in patients treated
with VEGF inhibitor–mTOR inhibitor–VEGF inhibitor
(OS 29.3 months; PFS 37.8 months). In a smaller study
comparing the treatment sequences TKI–everolimus–TKI
(n = 14) and TKI–TKI–everolimus (n = 19), both PFS
with the second agent (6.5 vs 11 months) and combined
PFS (23 vs 31 months) showed a trend in favor of the latter
sequence.[41] Furthermore, median OS was prolonged in
131 patients (treated with VEGF inhibitors in the first line)
who received TKI rather than mTOR inhibitor therapy in
the second line at the Institut Gustave Roussy (20.8 vs 16.6
months; p = 0.12).[42] Another retrospective analysis of
216 patients treated in the first line with VEGF-targeted
therapy (TKIs or bevacizumab) showed a significantly
longer (p = 0.014) time to treatment failure in the second
line when VEGF-targeted therapy (4.9 months) was com-
pared with mTOR inhibitors (2.5 months).[43]
At present, there are no clinical trial data evaluating the
efficacy of second-line axitinib or everolimus after first-line
pazopanib, but real-world experience provides some insight
into the use of VEGF inhibitors compared with mTOR inhi-
bitors following first-line pazopanib. For example, in a retro-
spective analysis of data from 35 patients treated in the second
line with everolimus or temsirolimus following first-line pazo-
panib, a PFS of 5.7 months and an OS of 16.0 months were
reported.[44] In a retrospective analysis, median PFS was sig-
nificantly prolonged (p = 0.009) in patients treated with anti-
VEGF therapy (n = 22, 5.6 months) compared with mTOR
inhibitor (n = 13, 2.4 months) following pazopanib therapy in
the first (n = 28) or second line (post cytokines; n = 7).[45]
Although axitinib was not one of the anti-VEGF therapies used,
20 of the 22 patients were treated with a VEGF-TKI, support-
ing the use of a second TKI after treatment with pazopanib.
These results contrast with those reported in a retrospective
analysis of data from patients treated with everolimus
(n = 233), temsirolimus (n = 178), or sorafenib (n = 123)
following first-line VEGF-TKI therapy, in which everolimus
significantly prolonged OS compared with sorafenib.[46]
However, as with other studies investigating the use of the
VEGF-TKI–mTOR inhibitor sequence, very few patients
were treated in the first line with pazopanib; therefore, it is
difficult to determine the clinical impact of these results with
regard to treatment sequencing.[46,47]
In this review, the current status of treatment second line
and beyond in CEE countries is considered, with a focus on
the challenges surrounding access to and reimbursement for
multiple lines of treatment. Its aim is to highlight both the
current status and the importance of patient access to effec-
tive therapies beyond first line.
3. Current status of sequential therapy in CEE
countries
To obtain up-to-date information on the situation in the
CEE region, an online questionnaire consisting of 31
questions about current practice in the management of
RCC was developed by a group of regional experts. The
questionnaire was distributed to oncologists and payers in
this region over the period July – September 2014. In
total, 40 responses were received from the following 15
countries: Belarus, Bosnia and Herzegovina, Bulgaria,
Croatia, Czech Republic, Estonia, Hungary, Kazakhstan,
Latvia, Poland, Romania, Serbia, Slovakia, Slovenia and
Turkey; these countries will be the focus of the review.
Kazakhstan and Turkey have been included because of
similarities in terms of the economic climate and health-
care systems between these countries and the CEE coun-
tries. Of the 40 respondents, 32 were clinicians and 8 were
payers. With the exception of two of four physicians from
Slovakia and one of five from Turkey, all physicians were
from the public sector or academic hospitals. Although
RCC is an uncommon disease, all respondents had a
relatively high level of experience with treating the disease:
26 of the 40 respondents indicated that their institutions
see > 20 new RCC patients per year and 8 respondents
indicated that their institutions see > 50 new RCC
patients per year. Following receipt of the completed ques-
tionnaires, the results were collated for each country and
shared with country-specific health economics and out-
comes research experts to ensure the data regarding access
and reimbursement were correct and to resolve any
inconsistencies.
3.1 Market access and reimbursement
In most of the 15 CEE countries, with the exception of
Serbia and Latvia, most RCC drugs are available (licensed)
and reimbursed. All RCC drugs are reimbursed in the Czech
Republic; all mRCC drugs except bevacizumab are
reimbursed in Turkey and all except bevacizumab and IL-2
are reimbursed in Hungary. There are, however, some restric-
tions in the region on availability; for example, only sunitinib
is reimbursed in Serbia. In addition, access to both axitinib
and IL-2 is limited to a minor extent as neither is approved
in Bosnia and Herzegovina or Bulgaria and axitinib is not
approved in Belarus. There are also restrictions on the reim-
bursement of RCC drugs, which is most commonly provided
by national funding (13 of 15 countries). A restriction
Vrdoljak et al.
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common to eight of the countries is that poor performance
status patients are not eligible to receive targeted therapy.
Similarly, in seven countries, Memorial Sloan Kettering
Cancer Center poor-risk patients are not eligible. A summary
of reimbursed RCC drugs is provided in Table 1. Another
potential barrier to RCC drug access in this region is the
requirement for special permission to be granted by either the
Ministry of Health/health authority, another government
organization, or an insurance company. Special permission
is required in seven countries (Belarus, Bosnia and
Herzegovina, Croatia, Poland, Romania, Serbia, Slovakia
and Turkey) before starting targeted treatment for mRCC
with most available drugs. Although special permission
usually takes < 4 weeks, delays in treatment initiation of
> 2 months were reported in Bosnia and Herzegovina.
With regard to the funding process, differences exist between
the CEE countries. In Belarus and Kazakhstan, there is
centralized procurement on a tender basis: the government
buys a quantity of each drug per year, which can be used in
any line but is only available while the supply lasts (personal
communication).
3.2 Second-line therapy
To evaluate the usage of second-line targeted therapies in the
CEE region, respondents were asked to estimate the propor-
tion of patients receiving second-line therapy both in their
country and within their center. Interestingly, there was a
trend for respondents to indicate that more patients received
second-line therapy at their own center compared with the
whole country, which may reflect the respondents’ high level
of experience in terms of the management of mRCC. In both
instances, the most usual estimate of the proportion of
patients receiving second-line therapy was 50 – 65%. This
proportion tended to be lower in countries with many restric-
tions to access, such as Bosnia and Herzegovina, where
sunitinib and everolimus are the only two mRCC drugs
reimbursed. In the CEE countries, there is very limited access
to third-line therapy. Throughout the CEE countries, more
respondents stated that they favored the sequential use of
TKIs (22 respondents) rather than TKI followed by mTOR
inhibitor in the first and second line (15 respondents). One
respondent stated that they favored the sequential use of
mTOR inhibitors.
In most countries considered, at least two lines of ther-
apy are reimbursed although with many restrictions.
Second-line therapy is completely unavailable in both
Latvia and Serbia and only one line of therapy is allowed.
The system in Slovakia is complex: all drugs for the treat-
ment of mRCC have to be discussed with the health
insurance company (HIC) representative and approval for
the reimbursement of treatment obtained every three
months.
Specific restrictions on reimbursement for everolimus, axi-
tinib and sorafenib in the second line are summarized in
Table 2. Everolimus is reimbursed following first-line tar-
geted therapy in 10 of the countries, including Turkey,
Poland and Hungary. In Kazakhstan, everolimus is
Table 1. Reimbursement of drugs for the treatment of mRCC in any line of therapy.
Country (n) Reimbursed mRCC treatments
Axitinib Bevacizumab Everolimus IFN-α IL-2 Pazopanib Sorafenib Sunitinib Temsirolimus
Belarus (n = 2) – ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Bosnia and Herzegovina (n = 1) – – ✓ – – – – ✓ –
Bulgaria* (n = 3) ✓ ✓ ✓ ✓ – ✓ ✓ ✓ ✓
Croatia (n = 2) ✓ – ✓ – ✓ ✓ ✓ ✓
Czech Republic (n = 5)* ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Estonia (n = 3) ✓ ✓ – ✓ – ✓ ✓ ✓ ✓
Hungary* (n = 3) ✓ – ✓ ✓ – ✓ ✓ ✓ ✓
Kazakhstan* (n = 2) – ✓ ✓ ✓ ✓ ✓ ✓ ✓ –
Latvia (n = 1) – – – ✓ – ✓ – – –
Poland (n = 4) ✓ – ✓ ✓ – ✓ ✓ ✓ –
Romania* (n = 2) – ✓ – ✓ – – ✓ ✓ ✓
Serbia (n = 1)* – – – – – – – ✓* –
Slovakia (n = 4)*,‡ –§ – ✓ ✓ – ✓ ✓ ✓ ✓
Slovenia (n = 2) – ✓ ✓ ✓ – ✓ ✓ ✓ ✓
Turkey (n = 5) ✓ – ✓ ✓ ✓ ✓ ✓ ✓ ✓
*Specific restrictions apply, including duration of previous lines of therapy (see Section 3.2 and Table 2).
‡The use of all drugs for the treatment of mRCC must be discussed with the HIC representative and approval for the reimbursement of treatment obtained every
3 months.
§Treatment costs are covered for a limited number of patients based on individual agreements with HICs.
HIC: Health insurance company; mRCC: Metastatic renal cell carcinoma.
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reimbursed following cytokine but not TKI therapy. Choice
of first-line agent, response to first-line agent, and patient
prognosis were the most common restrictions to the
reimbursement of everolimus. However, in two (Belarus
and Slovenia) out of the 10 countries in which everolimus
is reimbursed and there is more than one approved first-line
agent, choice of first-line treatment is not a restriction. The
use of axitinib following TKI therapy is currently reimbursed
in only six countries (Croatia, Czech Republic, Estonia,
Hungary, Poland and Turkey), as shown in Table 1; there
are many restrictions to reimbursement. Although axitinib is
not officially reimbursed in Slovakia, HICs cover the cost of
axitinib treatment for a limited number of patients. Within
these seven countries there are many restrictions to
reimbursement. For instance, although everolimus is
reimbursed following any VEGF-targeted therapy in the
Czech Republic and Hungary, axitinib is only reimbursed
following first-line treatment with sunitinib. In Turkey, cyto-
kines must be used in the first line, following which axitinib
can be used in the second line, or the third line following a
different VEGF-targeted therapy, whereas everolimus is
reimbursed only in the third line following VEGF-targeted
therapy. Sorafenib (which is recommended as an option
rather than standard treatment in the ESMO guidelines) is
officially reimbursed following TKI treatment in only four
countries, but is reimbursed in a further eight countries
following prior cytokine treatment.
Respondents indicated that the most common reason for
switching from first-line to second-line therapy was disease
progression. Furthermore, nearly half (n = 20) of the respon-
dents – including those from Hungary and Poland – indicated
that authorities require first-line treatment to be terminated
following RECIST-defined progression. However, 13 respon-
dents indicated that in some instances the patient is allowed to
remain on therapy despite evidence of progressive disease; for
example, if it can be managed with local therapy or if QoL is
maintained and patient is still benefiting. In most countries,
the oncologist is responsible for determining whether progres-
sion has occurred; however, in Belarus, Croatia and some
centers in the Czech Republic, Estonia, Slovakia and Turkey,
the radiologist is responsible. In most countries, second-line
treatment is not affected by the duration of first-line therapy,
but in Bulgaria, Kazakhstan and Romania the patient must
have received ≥ 3 months of first-line targeted therapy; this
increases in Slovakia to ≥ 6 months before initiating second-
line treatment. In Hungary, axitinib cannot be used if the
patient progressed within the first 3 months of first-line treat-
ment with sunitinib, whereas everolimus can be used regardless
of the duration of first-line therapy; thus, it can be used in
cases of primary resistance to the first-line TKI. In Turkey, the
Box 1. The status of second and subsequent lines of treatment for renal cell carcinoma in Russia.
In addition to the 15 countries that are the focus of this review, 11 responses were received from Russia. Owing to the major
differences between Russia and the rest of the Central and Eastern European (CEE) region in the availability and reimbursement of
targeted agents, the situation in Russia is considered separately. In Russia, major differences also exist between regions; therefore,
the situation in seven regions (North West, Moscow, East Siberia, West Siberia, Volga and South) was analyzed.
The reimbursement system in Russia is complex; therefore, reimbursement experts in the region were contacted to clarify the
responses received. The federal essential drug list details the drugs that should be provided free of charge or at a discounted price
by the state; the price of each drug must be listed. With regard to targeted agents for metastatic renal cell carcinoma (mRCC), only
sunitinib, everolimus, sorafenib and bevacizumab appear on the essential drug list. Reimbursement for drugs is possible through
other routes, although they are based on the essential drug list. All targeted therapies, with the exception of axitinib, are listed for
reimbursement through some route in at least one region. There are two outpatient programs: the additional medical supplies
program (DLO), in which regional reimbursement is provided to specific disease groups, particularly severe or chronic diseases
(such as cancer); and the essential drug coverage program (ONLS), which is a reimbursement program that operates on a regional
level. For both inpatients and outpatients, reimbursement may be provided through the outpatient–inpatient (OMI) program.
Reimbursement may also be granted by special request to the regional Ministry of Health. Reimbursement routes for targeted
agents are summarized in Table 3. Access to axitinib is highly restricted because reimbursement is only possible through special
request to the regional Ministry of Health. Respondents indicated that reimbursement authorization for most RCC drugs takes an
average of 2 ─ 4 weeks and that excessive cost/lack of cost-effectiveness data were the most common reasons that drugs for
mRCC are not recommended for reimbursement.
The complexity of the reimbursement system in Russia was reflected in the answers given by the respondents. Many answers from
respondents within the same region were inconsistent, suggesting a lack of understanding of the reimbursement processes. Most
respondents (n = 7) stated that three or more lines of targeted therapy are reimbursed. However, there was inconsistency between
and within regions about whether second-line reimbursement is (n = 7) or is not (n = 3) affected by the choice of first-line therapy.
Similar to other countries, disease progression – determined by the oncologist – is the most frequent determinant of the switch
from first- to second-line targeted therapy. Most respondents (n = 9) indicated that second-line treatment is not affected by the
duration of first-line targeted therapy.
In Russia, the complex reimbursement system and the limited financial resources allocated to cancer treatment are the main
obstacles restricting patient access to second-line treatments. Action must be taken to ensure physicians have a clear under-
standing of the process and also to raise awareness of the benefits of targeted therapies with few reimbursement options, with a
focus on axitinib.
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prescription for first-line treatment is written for 6 months,
but treatment can be changed earlier if progression occurs.
3.3 Requirements for health economic data
In most of the CEE countries (Bosnia and Herzegovina,
Croatia, Czech Republic, Estonia, Hungary, Latvia, Poland,
Romania, Serbia, Slovakia, Slovenia and Turkey), health
outcomes/pharmacoeconomic data are required as part of the
negotiations for reimbursement. Respondents indicated that
lack of cost-effectiveness data and budget-impact estimates
data were the main reasons why drugs for the treatment of
mRCC are not accepted for reimbursement; lack of OS data
was mentioned by respondents from the Czech Republic and
Poland. In Serbia, criteria for reimbursement are currently
under discussion and oncologists have suggested that, given
the lack of resources, priority should be given to OS data.
Following questionnaire data collation, it was necessary to
verify the answers about health economic data requirements
with health economics and outcomes research experts. This
process highlighted the possible lack of awareness among
respondents on these specific requirements for reimbursement.
4. Discussion
4.1 Market access and reimbursement
The data presented in this review indicate that the situation
regarding access to targeted treatment varies throughout the
CEE region. The initiation of targeted treatment can be
delayed when special permission is required for reimburse-
ment approval. Access to axitinib in particular is limited in
this region. The clinical benefits of axitinib, everolimus and
sorafenib post sunitinib have been demonstrated in clinical
trials, and axitinib and everolimus are recommended in the
ESMO guidelines.[10,18,24] The data from this survey also
highlighted the reimbursement restrictions preventing poor
performance status and Memorial Sloan Kettering Cancer
Center poor-prognosis patients from accessing second-line
targeted treatment.
4.2 Second-line therapy
The clear benefit of targeted therapy in the second line and
beyond is supported by clinical trials and real-world data.
[18,20–26,32,48] Estimates from respondents indicated that
50 – 65% of patients are receiving second-line treatment,
which is quite high compared with that previously reported;
for example, in the RECORD-3 trial, only 43% of 471
patients received second-line treatment.[49] Similarly, analy-
sis of data from 2705 patients from the International mRCC
Database Consortium showed that only 43% of patients
received treatment in the second line and beyond.[26]
However, the respondents’ estimates are likely to be more
reflective of current practices than the figures reported in
studies done several years ago. It is important, however, to
emphasize that respondents in the current study were based
at centers that had high levels of experience; therefore, it is
likely that their answers represent best practice and not
necessarily the country as a whole. Respondents were asked
to indicate the proportion of patients receiving second-line
treatment in the country as a whole; however, the data
provided were estimates and possibly influenced by experi-
ences at their own center. In addition, it is possible that these
data are masked by poor access to first-line treatment.
It is interesting to consider differences in the
reimbursement restrictions applied to everolimus and axitinib
in several countries in relation to the available on treatment
sequencing. As discussed in Section 2.1, the efficacy of axi-
tinib following first-line treatment with sunitinib was evi-
denced in the AXIS trial and axitinib is reimbursed only
following sunitinib therapy in the Czech Republic and
Hungary. By contrast, despite the lack of clinical data
about the efficacy of everolimus following first-line treatment
with pazopanib, it is reimbursed following any VEGF-tar-
geted therapy in the Czech Republic and Hungary.
Conversely, in Turkey, axitinib is reimbursed following
both first-line cytokine therapy and VEGF-targeted therapy
following first-line cytokine therapy, whereas everolimus is
only reimbursed following first-line cytokine therapy and
second-line VEGF-targeted therapy. This illustrates the fact
that sometimes indications outlined in drug-marketing
authorizations are not reflective of the investigated drug
sequences within the registration trial. For example, in its
summary of product characteristics, axitinib is indicated for
use following sunitinib treatment only, whereas according to
the FDA label it can be used after any type of first-line
Table 3. Reimbursement for targeted agents for patients
with mRCC in Russia.
Essential drug
program (ONLS)/
additional medical
supplies program
(DLO)
OMI
program
Regional
reimbursement on
patient request to
the regional
Ministry of Health
Axitinib – – ✓
Bevacizumab ✓ In some
regions
✓
Everolimus – In some
regions
✓
Pazopanib – In some
regions
✓
Sorafenib – In some
regions
–
Sunitinib – In some
regions
✓
Temsirolimus – In some
regions
–
OMI: Outpatient–inpatient; ONLS: Essential drug coverage program; mRCC:
Metastatic renal cell carcinoma.
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systemic therapy. By contrast, in Europe, everolimus is indi-
cated for use after first-line TKI therapy, whereas the FDA
label covers its use only after sunitinib or sorafenib treatment.
These discrepancies highlight the need to determine optimal
treatment sequences and to ensure they are available to
patients.
Disease progression is the most common reason for the
switch from first- to second-line therapy. Use of RECIST may
result in patients with a mixed response being considered to
have disease progression.[50] This could result in the termina-
tion of therapy in patients who may otherwise continue to
receive clinical benefit.[39,51] In five CEE countries, duration
of first-line treatment was indicated as a restriction to second-
line treatment. However, as some data suggest that there is no
relationship between responses to first- and second-line agents
[37,52] or duration of response to first-line therapy,[22] it is not
appropriate to the latter to determine the choice of second-line
therapy when establishing the optimal treatment strategy.
Despite the fact that no mTOR inhibitor is recommended in
the first line for good- or intermediate-prognosis patients, one
respondent indicated that their favored treatment sequence was
sequential mTOR inhibitors.
4.3 Requirements for health economic data
The limited economic resources in CEE countries are
likely to restrict access to second-line treatments. As dis-
cussed earlier, cost-effectiveness data are important in
determining whether RCC drugs are reimbursed.
Although data are limited, several studies have demon-
strated the cost-effectiveness of second-line treatments.
An extensive literature review of US-based studies per-
formed between January 2001 and February 2013 indi-
cated that the use of second-line targeted agents was cost-
effective in patients following failure of the first-line agent.
[53] Results from this study also indicated that drugs
administered orally, rather than intravenously, were more
cost-effective. One method to determine whether a treat-
ment is economically feasible is to assess the number of
total life-years and quality-adjusted life-years gained.[7]
Using this method, second-line sorafenib was shown to
be more cost-effective than best supportive care.[54] By
contrast, the use of second-line everolimus was deemed not
to be cost-effective compared with best supportive care.
[55] However, in a study where the two were directly
compared, the results indicated that everolimus was more
cost-effective.[56]
5. Conclusions
In this review, access to second-line RCC treatments in the
CEE region was considered. The data obtained through
questionnaires showed that, although most RCC drugs are
licensed and reimbursed in the 15 countries considered, there
are numerous restrictions to reimbursement and access is
varied. In most countries considered at least two lines of
therapy are reimbursed, although with many restrictions
that are not necessarily reflective of clinical benefit; access
to axitinib in particular is limited in this region.
Increased access to optimal treatment strategies will be
highly effective in tackling the high mortality rates associated
with mRCC in this region; therefore, it is important that
action is taken to increase awareness of the benefits of
sequential targeted treatment and to ensure reimbursement
systems are reflective of this.
6. Expert opinion
Access to second-line therapy has many obstacles in CEE
countries, including the limited availability of drugs,
reimbursement restrictions, lack of cost-effectiveness data
for mRCC drugs and the complexity of some reimbursement
systems. As a result, patients with mRCC are unlikely to be
receiving optimal treatment. Considering the clinical benefits
of therapy second line and beyond, action needs to be taken
so that patients with mRCC have access to multiple lines of
therapy. It is of great importance to ensure that there is wide
access in all CEE countries to the standard drugs recom-
mended after progression on VEGF-targeted therapy, namely
axitinib and everolimus. Although everolimus and axitinib
are reimbursed in the second line in several countries, includ-
ing Poland, Hungary and Turkey, there are various restric-
tions, including those based on duration and choice of first-
line treatment. Therefore, to ensure that patients are receiv-
ing optimal treatment, steps must be taken to ensure that
reimbursement restrictions are relevant to clinical benefit. In
addition, in countries where the options for several lines of
treatment are limited, such as Bosnia and Herzegovina,
Latvia and Serbia, the benefits of such treatment must be
highlighted and changes to reimbursement restrictions
encouraged so that they reflect optimal treatment strategies.
In addition, much work is required in Serbia to ensure that
patients have access to more than one option (sunitinib) of
targeted therapy. Access to targeted treatments for poor-
prognosis patients also needs to be improved as they are at
present limited by reimbursement restrictions in many CEE
countries. Furthermore, action must be taken throughout the
CEE region to ensure increased access to agents in the third
line.
To overcome problems associated with reimbursement
restrictions, the benefits of treating mRCC using multiple
lines of treatment must be highlighted to payers and physi-
cians. As discussed earlier in many CEE countries – including
Hungary, Poland and Turkey – health/pharmaco-economic
data are required for reimbursement approval. Increased
knowledge of the reimbursement system by physicians will
benefit patients and help to ensure that they have access to all
available optimal treatments. In countries such as Slovakia, in
which reimbursement approval is required from HICs, it is
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particularly important that actions are taken to ensure indi-
viduals working for HICs are aware of the clinical benefits of
the use of targeted treatments as well as the individual needs
of the patient. The substantial cost of AEs has a large impact
on the cost-effectiveness of targeted treatments; therefore, it
is essential to ensure that healthcare professionals are aware of
how to effectively manage AEs.[17]
The data presented in this article indicate that the reasons
used by clinicians to decide whether to switch to second-line
treatment may not be based on clinical benefit. For example,
many clinicians in CEE countries – including in Hungary
and Poland – are required to use RECIST to define progres-
sion and then terminate treatment. It is, therefore, of great
importance to ensure that the physician responsible is able to
accurately interpret tumor images and define progression.
Physicians should also be made aware of the evidence from
clinical trials that highlight the benefits of sequential TKIs in
addition to the lack of evidence to support the use of
sequential mTOR inhibitors.
Increasing awareness of clinical trial and cost-effectiveness
data as well as tackling obstacles associated with reimburse-
ment restrictions will increase the number of treatment
options available to patients with mRCC in the CEE region.
Increased access to optimal treatment strategies will be highly
effective in tackling the high mortality rates associated with
mRCC in this region.
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